

Clinical Trial Protocol

Iranian Registry of Clinical Trials

17 Sep 2026

Comparing efficacy of dolutegravir plus tenofovir alafenamide as dual-drug regimen with the standard triple-drug regimen in HIV positive patients

Protocol summary

Study aim

This study has been designed to compare efficacy of dolutegravir plus tenofovir alafenamide as a double-drug regimen with the standard triple-drug regimen in HIV positive patients with undetectable viral load.

Design

This is an open-label randomized clinical trial. Eighty HIV positive patients will be assigned to the intervention or the control group according to the simple randomization method.

Settings and conduct

Patients who referred to the HIV clinic of Imam Khomeini Hospital Complex (affiliated with Tehran University of Medical Sciences) for their treatment follow-up will be evaluated for the inclusion criteria of the study. Eligible patients will be included in study after that sign the consent form.

Participants/Inclusion and exclusion criteria

Inclusion criteria are: -Adults older than 18 years old -HIV positive patients with undetectable viral load for at least 2 years -HIV positive patients with CD4 cells count >200 for at least 2 years -Patients who are on first line antiretroviral therapy for at least 2 years -No any mutation against INSTI or NRTI drugs -Adequate adherence to treatment -No any AIDS-related event (opportunistic infection or cancer) Exclusion criteria are: -Pregnant or lactating women -Concomitant viral co-infections including hepatitis B or C -Existing any co-morbidity that requiring treatment which may have significant interactions with ART -Renal or hepatic diseases

Intervention groups

Intervention group : Standard ART regimen (triple-drug regimen) will be changed to dual regimen including dolutegravir plus tenofovir alafenamide (DTG plus TAF) Control group: The patients' standard regimen (triple-drug regimen) will be continued. Duration of intervention

and follow-up in the both groups is 48 weeks.

Main outcome variables

HIV viral load CD4 cells count Adverse drug reactions Adherence to treatment

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20191005044984N1**

Registration date: **2019-12-21, 1398/09/30**

Registration timing: **registered_while_recruiting**

Last update: **2019-12-21, 1398/09/30**

Update count: **0**

Registration date

2019-12-21, 1398/09/30

Registrant information

Name

Golbarg Alavian

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 6658 1598

Email address

golbarg.alavian@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-11-22, 1398/09/01

Expected recruitment end date

2020-02-19, 1398/11/30

Actual recruitment start date

empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Comparing efficacy of dolutegravir plus tenofovir alafenamide as dual-drug regimen with the standard triple-drug regimen in HIV positive patients

Public title
Dolutegravir plus tenofovir alafenamide as a double-drug regimen in HIV positive patients

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
 Adults older than 18 years old HIV positive patients with undetectable viral load for at least 2 years HIV positive patients with CD4 cells count >200 for at least 2 years Patients who are on first line antiretroviral therapy for at least 2 years No any mutation against INSTI or NRTI drugs Adequate adherence to treatment No any AIDS-related event (opportunistic infection or cancer)
Exclusion criteria:
 Pregnancy and lactation Concomitant viral co-infections including hepatitis B or C Existing any co-morbidity that requiring treatment which may have significant interactions with ART Renal or hepatic diseases

Age
From **18 years** old

Gender
Both

Phase
3

Groups that have been masked
No information

Sample size
Target sample size: **80**

Randomization (investigator's opinion)
Randomized

Randomization description
Eligible patients will be assigned to the intervention or the control group using simple randomization method. The random numbers will be created by a computer program. The random numbers will be sent to satellite pharmacy of the HIV clinic. Eligible patients will be introduced to this department and treatment regimen will be assigned accordingly.

Blinding (investigator's opinion)
Not blinded

Blinding description

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids
empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Tehran University Of Medical Scienses

Street address

Ghods Ave.

City

Tehran

Province

Tehran

Postal code

۱۴۱۹۷۳۳۱۴۱

Approval date

2019-09-30, 1398/07/08

Ethics committee reference number

IR.TUMS.TIPS.REC.1398.087

Health conditions studied

1

Description of health condition studied

Virologically Undetectable HIV Patients

ICD-10 code

ICD-10 code description

Primary outcomes

1

Description

Virological response: Maintain HIV-RNA viral load <50 copies / ml in response to the ART regimen during the study course

Timepoint

Control group: At baseline and weeks 24 and 48

Intervention group: At baseline and weeks 8, 24 and 48

Method of measurement

LightCycler® 96 Real-Time PCR, Roche, with a limit of 40 copies / ml

2

Description

Immunological response: Increase or maintenance of CD4 cells count > 200 cells/mm³ during the study period

Timepoint

Control group: At baseline and weeks 24 and 48

Intervention group: At baseline and weeks 8, 24 and 48

Method of measurement

Flowcytometry

3

Description

Adverse reactions : Any new sign or symptom caused by the regimens

Timepoint

Control group: At baseline and weeks 24 and 48
Intervention group: At baseline and weeks 8, 24 and 48
Method of measurement
Interview and patient' report

4

Description

Adherence to treatment

Timepoint

Control group: At baseline and weeks 24 and 48

Intervention group: At baseline and weeks 8, 24 and 48

Method of measurement

Interview and pill count methods

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: The patients' previous standard triple-drug regimen will be changed to the dual-drug regimen including dolutegravir tablet, 50 mg daily plus tenofovir alafenamide tablet, 25 mg daily. This change will be continued for 48 weeks. Patients will be followed during the study period.

Category

Treatment - Drugs

2

Description

Control group: The patients' previous standard triple-drug regimen will be continued. Patients will be followed for 48 weeks.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

HIV Clinic affiliated to Imam Khomeini Hospital Complex

Full name of responsible person

Ladan Abbassian

Street address

Imam Khomeini Hospital Complex, Gharib Ave., Keshavarz Blvd.

City

Tehran

Province

Tehran

Postal code

1419733141

Phone

+98 21 6658 1598

Email

La.abbasian@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Mohammad Ali Sahraian

Street address

Vice Chancellor for Research, Tehran University of Medical Sciences, Ghods Ave., Tehran, Iran

City

Tehran

Province

Tehran

Postal code

02166706141

Phone

+98 21 8898 7381

Email

msahrai@sina.tums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Tehran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Hossein Khalili

Position

Professor

Latest degree

Specialist

Other areas of specialty/work

Medical Pharmacy

Street address

Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, 16 Azar Ave., Tehran, Iran

City
Tehran
Province
Tehran
Postal code
1417614411
Phone
+98 21 6658 1598
Email
Khaliliah@tums.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Ladan Abbasian
Position
Associate professor
Latest degree
Medical doctor
Other areas of specialty/work
Infectious diseases
Street address
Imam Khomeini Hospital Complex., Gharib Ave.,
Keshavarz Blvd.
City
Tehran
Province
Tehran
Postal code
1419733141
Phone
+98 21 6658 1598
Email
La.abbasian@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Hossein Khalili
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Medical Pharmacy
Street address
Department of Clinical Pharmacy, Faculty of
Pharmacy, Tehran University of Medical Sciences, 16

Azar Ave., Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1417614411
Phone
+98 21 6658 1598
Email
Khaliliah@tums.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available

Title and more details about the data/document

Results of the study will be published. The study protocol and statistical analysis will be included in the manuscript.

When the data will become available and for how long

One year after finishing the study, data will be published and will be available in databases.

To whom data/document is available

After permission from the sponsor, data of the study will be available for academic researchers, physicians and scientific institutes.

Under which criteria data/document could be used

Other researchers are permitted to include the results in their systematic reviews and meta-analysis.

From where data/document is obtainable

Contact scientific responsible person for the clinical trial as needed.

What processes are involved for a request to access data/document

After receiving the query, dependent on the requested data, the scientific responsible person of the study will respond to the query in coordinate with the sponsor within 2 weeks.

Comments